Type-2 diabetes

Article Type: Food facts From: Nutrition & Food Science, Volume 40, Issue 6.

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to announce that the global licensing agreement with sanofi-aventis has been amended to provide for the development and commercialisation of Lixisenatide (AVE0010/ZP10) in combination with Lantus^®, sanofi-aventis' recombinant human insulin analogue.